Global Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics  Market, By Type (AP-001, AP-1, DM-204, Neu-120, Others),  Indication (Musculoskeletal Disorder, Lung Cancer, Dyskinesia, Menkes Disease, Inflammatory Disease, Others),  Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy),  End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028